I think the path that CytoDyn chose is brilliant. Let the FDA decide on the EUA application while the data of the unblinded data is with the statisticians so they can grant or not before the top line report is released. If they grant EUA it will be hard for detractors to heavily criticize the TLD. If FDA does not approve the EUA and the TLD shows good SAT SIG results on overall mortality then that would seem to put an onus on the FDA to answer the question why a safe and life saving drug is being denied immediate use in this pandemic.
Market Data 
Markets 
AI
